Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by rapman58on Feb 14, 2007 4:20pm

637 Views

Post# 12236681

RE: 100 shares before the bell... lol

and I picked up the 500 b4 that at 24.52..had fun today on the swings bought and sold 2000..for a net $1500 profit.. I think we will be down tomorrow b4 we go up.. chgo, today's close at $24.90 has a certain irony to it, the old FCP high, while it is now scraping old lows!

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages